DRUG · Mapped RxNorm record
insulin degludec
Normalized identity: insulin degludecView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
NCT01068678
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
insulin glargine
Normalized identity: insulin glargineView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedComparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Diabetesverified · MONDO: diabetes mellitus
Interventions
insulin degludecDRUG · verified · RxNorm: insulin degludec
insulin glargineDRUG · verified · RxNorm: insulin glargine
Sponsors & collaborators
Novo Nordisk A/Slead sponsor
Mapped research locations
TorontoOntario, Canada3HoustonTexas, United States2DallasTexas, United States1AtlantaGeorgia, United States1San AntonioTexas, United States1NashvilleTennessee, United States1ClevelandOhio, United States1DurhamNorth Carolina, United States1IndianapolisIndiana, United States1Salt Lake CityUtah, United States1CharlestonSouth Carolina, United States1RichmondVirginia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01068678 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.